148 related articles for article (PubMed ID: 23573743)
1. [Age-related visual loss].
Neubauer AS; Kernt M
MMW Fortschr Med; 2013 Feb; 155(2):36-7. PubMed ID: 23573743
[No Abstract] [Full Text] [Related]
2. Why using Avastin for eye disease is so difficult.
Torjesen I
BMJ; 2012 May; 344():e3012. PubMed ID: 22549057
[No Abstract] [Full Text] [Related]
3. Drugs for macular degeneration, price discrimination, and Medicare’s responsibility not to overpay.
Silver J
JAMA; 2014 Jul; 312(1):23-4. PubMed ID: 24860863
[No Abstract] [Full Text] [Related]
4. Bevacizumab (AVASTIN) and age-related macular degeneration. Lower cost does not justify taking risks.
Prescrire Int; 2015 Sep; 24(163):201-4. PubMed ID: 26417625
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab versus ranibizumab: why are we not playing the joker?
Banfi R; Attanasio F; Palazzi N; Colombini S; Falai T; Cecchi M; Virgili G
Int J Clin Pharm; 2013 Aug; 35(4):507-9. PubMed ID: 23625322
[No Abstract] [Full Text] [Related]
6. A clearer view of evidence in treating macular degeneration: off-label policies and independent research.
Formoso G; Marata AM; Magrini N; Bero L
Cochrane Database Syst Rev; 2014 Sep; 2014(9):ED000090. PubMed ID: 25228121
[No Abstract] [Full Text] [Related]
7. Comparative effectiveness of anti-growth factor therapies for diabetic macular edema: summary of primary findings and conclusions.
O'Malley PG
Arch Intern Med; 2012 Jul; 172(13):1014-5. PubMed ID: 22688778
[No Abstract] [Full Text] [Related]
8. [Avastin-Lucentis: off-label and surroundings].
Messori A
Recenti Prog Med; 2014 Apr; 105(4):137-40. PubMed ID: 24770536
[TBL] [Abstract][Full Text] [Related]
9. Managed care opportunities and approaches to supporting appropriate selection of treatment for sight preservation.
Cannon E
Am J Manag Care; 2019 Jul; 25(10 Suppl):S182-S187. PubMed ID: 31419089
[TBL] [Abstract][Full Text] [Related]
10. Response to Replacing ranibizumab with bevacizumab on the Pharmaceutical Benefits Scheme: where does the current evidence leave us?
O'Shea JG
Clin Exp Optom; 2012 Sep; 95(5):541-3. PubMed ID: 22672003
[No Abstract] [Full Text] [Related]
11. [Age-related macular degeneration].
Kernt M; Wolf A; Kampik A
MMW Fortschr Med; 2013 Feb; 155(2):43-5; quiz 46-7. PubMed ID: 23573745
[No Abstract] [Full Text] [Related]
12. A licence to cure.
Aronson JK; Ferner RE
BMJ; 2015 Apr; 350():h1723. PubMed ID: 25834026
[No Abstract] [Full Text] [Related]
13. Avastin is as effective as Lucentis for wet AMD and could save NHS 84m pound a year, study shows.
Hawkes N
BMJ; 2012 May; 344():e3275. PubMed ID: 22573655
[No Abstract] [Full Text] [Related]
14. Saving money on the PBS: ranibizumab or bevacizumab for neovascular macular degeneration?
Harvey KJ; Day RO; Campbell WG; Lipworth W
Med J Aust; 2011 Jun; 194(11):567-8. PubMed ID: 21644867
[TBL] [Abstract][Full Text] [Related]
15. Ocular and systemic safety of bevacizumab and ranibizumab in patients with neovascular age-related macular degeneration.
Johnson D; Sharma S
Curr Opin Ophthalmol; 2013 May; 24(3):205-12. PubMed ID: 23518613
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial.
Dakin HA; Wordsworth S; Rogers CA; Abangma G; Raftery J; Harding SP; Lotery AJ; Downes SM; Chakravarthy U; Reeves BC;
BMJ Open; 2014 Jul; 4(7):e005094. PubMed ID: 25079928
[TBL] [Abstract][Full Text] [Related]
17. The results of switching between 2 anti-VEGF drugs, bevacizumab and ranibizumab, in the treatment of neovascular age-related macular degeneration.
Aslankurt M; Aslan L; Aksoy A; Erden B; Cekiç O
Eur J Ophthalmol; 2013; 23(4):553-7. PubMed ID: 23516253
[TBL] [Abstract][Full Text] [Related]
18. Cost comparison of intravitreal aflibercept with bevacizumab and ranibizumab for the treatment of wet age-related macular degeneration.
Shaikh AH; Toussaint BW; Miller DM; Petersen MR; Foster RE; Riemann CD; Hutchins RK; Sisk RA
Ophthalmic Surg Lasers Imaging Retina; 2015 Jan; 46(1):62-6. PubMed ID: 25559511
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab in ophthalmology: the controversy moves forward.
Gillies MC
Clin Exp Ophthalmol; 2010 May; 38(4):333-4. PubMed ID: 20642588
[No Abstract] [Full Text] [Related]
20. Ranibizumab versus bevacizumab for the treatment of neovascular age-related macular degeneration.
Abouammoh M; Sharma S
Curr Opin Ophthalmol; 2011 May; 22(3):152-8. PubMed ID: 21483262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
